NLRP3 Inflammasome Inhibition in Inflammatory Disorders

The NLRP3 inflammasome is a cytosolic multiprotein complex that senses a wide array of pathogen‐ and damage‐associated molecular patterns to initiate innate immune responses. On activation, NLRP3 undergoes conformational changes and oligomerisation, recruiting the adaptor ASC and caspase-1 to form a platform for the maturation and release of interleukin-1β, interleukin-18 and the executioner of pyroptotic cell death, gasdermin D. Aberrant or persistent activation of NLRP3 drives chronic inflammation in conditions ranging from metabolic syndrome and cardiovascular disease to neurodegeneration and autoinflammatory syndromes. Consequently, selective inhibition of NLRP3 has emerged as a promising therapeutic strategy. Recent advances have elucidated molecular structures, interaction sites and conformational transitions of NLRP3, furnishing a framework for the rational design of small molecules and the repurposing of established drugs. Preclinical models demonstrate that inhibition of NLRP3 can attenuate tissue damage, restore homeostasis and slow disease progression, underscoring its global significance in tackling inflammatory disorders.

Research from Nature Portfolio

Recent studies have identified covalent and non-covalent inhibitors that directly target key domains of NLRP3. One investigation revealed that a natural diterpenoid forms a covalent bond with a critical cysteine residue in the NACHT domain, blocking interaction with the kinase NEK7 and preventing inflammasome assembly. This agent showed both preventive and therapeutic efficacy in mouse models of peritonitis, gouty arthritis and type 2 diabetes. Another report demonstrated that certain fenamate non-steroidal anti-inflammatory drugs selectively inhibit NLRP3 activation by modulating volume-regulated anion channels in macrophages, independently of cyclooxygenase inhibition. In rodent models of amyloid-β-induced memory loss and genetic Alzheimer’s disease, these fenamates reduced neuroinflammation and preserved cognitive function, highlighting opportunities for drug repurposing.

NLRP3 Inflammasome Inhibition in Inflammatory Disorders publication trend

The graph below shows the total number of articles in nlrp3 inflammasome inhibition in inflammatory disorders across all publications each year (not limited to Nature Index journals).

Technical terms

NLRP3 inflammasome: A supramolecular complex that activates caspase-1, leading to the processing and secretion of proinflammatory cytokines.

Pyroptosis: A form of regulated cell death characterised by cell swelling, membrane pore formation and release of inflammatory mediators.

DAMPs: Endogenous danger signals released from damaged or stressed cells that trigger innate immune sensors.

Oligomerisation: The process by which individual protein units assemble into a multimeric complex.

NACHT domain: A conserved nucleotide-binding region in NLRP3 essential for its activation and target for many inhibitors.

References

1. Pharmacological Inhibition of the NLRP3 Inflammasome: Structure, Molecular Activation, and Inhibitor-NLRP3 Interaction. Pharmacological Reviews (2023).
2. Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity. Nature Communications (2018).
3. Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer’s disease in rodent models. Nature Communications (2016).
4. UK5099 Inhibits the NLRP3 Inflammasome Independently of its Long‐Established Target Mitochondrial Pyruvate Carrier. Advanced Science (2024).
5. NLRP3 inflammasome in neuroinflammation and central nervous system diseases. Cellular & Molecular Immunology (2025).